Cell Therapy Slows Upper Limb Decline in Duchenne Muscular Dystrophy
The investigational cell therapy deramiocel slowed upper limb functional decline in boys and young men with Duchenne muscular dystrophy, data from the phase III HOPE-3 trial showed. At 12 months, the mean percent change from baseline in Performance of Upper Limb 2.0 (PUL 2.0) total score was −3.86 in the deramiocel group and −8.41 in…
